Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
PerkinElmer will acquire Oxford Immunotec for $22.00 per share, valuing the deal at approximately $591 million. This acquisition, expected to close by mid-2021, represents a premium of 28.3% compared to Oxford Immunotec's last closing price and significantly enhances PerkinElmer's portfolio in infectious disease testing, particularly for tuberculosis. PerkinElmer anticipates the deal to be modestly accretive to earnings in the first year and expects Oxford Immunotec's sales growth to outpace its own Diagnostics franchise. Oxford Immunotec will become a privately held company post-acquisition.
PerkinElmer (NYSE: PKI) has announced its participation in the J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 a.m. ET. CEO Prahlad Singh will present updates on the company’s strategic priorities. The presentation will be accessible via a live audio webcast on PerkinElmer's investor relations website, with a replay available for 90 days post-event. In 2019, PerkinElmer generated approximately $2.9 billion in revenue and operates globally with about 14,000 employees.
PerkinElmer (NYSE: PKI) announced the launch of the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) by its subsidiary EUROIMMUN, a quantitative test for IgG antibodies against the SARS-CoV-2 S1 antigen. This assay supports vaccine development and may help assess immunity in previously infected individuals. EUROIMMUN aims to file for FDA Emergency Use Authorization (EUA). Production capacity has increased to over three million tests weekly, facilitating significant contributions to global epidemiological studies.
PerkinElmer (NYSE: PKI) will participate in the Wolfe Virtual Healthcare Conference on November 19 at 11:25 a.m. ET. The company's CEO, Prahlad Singh, is set to provide an update on the company's strategic priorities. A live audio webcast can be accessed through the Investors section of PerkinElmer's website, where a replay will also be available for 90 days after the event. PerkinElmer reported approximately $2.9 billion in revenue in 2019, employing about 13,000 people globally.
PerkinElmer, a leader in health innovation, announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 1:20 p.m. ET. Jamey Mock, SVP and CFO, will discuss the company's strategic priorities and updates. A live audio webcast will be accessible on the company’s Investors webpage, with a replay available for 90 days post-event. In 2019, PerkinElmer reported revenues of approximately $2.9 billion and has a workforce of around 13,000 employees across 190 countries.
PerkinElmer (NYSE: PKI) has announced a recommended all-cash offer to acquire Horizon Discovery Group (LSE: HZD) for approximately $383 million. This acquisition, expected to close in Q1 2021, aims to enhance PerkinElmer's life sciences portfolio with gene editing and gene modulation tools. Horizon, headquartered in the UK, generated $75.5 million in revenue in 2019 and specializes in CRISPR and RNAi technologies. PerkinElmer anticipates the acquisition will modestly boost non-GAAP earnings in the first year and position Horizon favorably in a growing market.
PerkinElmer (NYSE: PKI) announced that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has been cleared for marketing as an in vitro diagnostic device in over 30 countries, complying with the European In Vitro Diagnostic Directive. The test, currently under U.S. FDA review for Emergency Use Authorization, enables detection of SARS-CoV-2, influenza A, influenza B, and RSV from a single sample, crucial for coping with increased testing demands during flu season. The panel is designed to work with PerkinElmer's automated systems for enhanced efficiency in virus detection.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, payable on February 12, 2021, to shareholders of record by January 22, 2021. This announcement highlights the company's commitment to returning value to its shareholders.
PerkinElmer reported revenue of approximately $2.9 billion in 2019, employing about 13,000 staff across 190 countries. The company is a key player in the S&P 500 Index.
Summary not available.
PerkinElmer, Inc. (NYSE: PKI) projects a 35% increase in reported revenue and a 33% rise in organic revenue for Q3 2020, driven by strong demand for its COVID-19 testing solutions, contributing approximately $280 million to the quarterly revenue. The financial results will be disclosed after market close on October 28, 2020, followed by a conference call hosted by the executive team.
FAQ
What is the market cap of PERKINELMER (PKI)?
